Immunic initiated with an Outperform at William Blair

William Blair initiated coverage of Immunic (IMUX) with an Outperform rating and $6.80 fair value estimate. Immunic is a late-stage clinical company developing lead asset vidofludimus calcium for multiple sclerosis, the analyst tells investors in a research note. The firm believes vidofludimus could command market share as an oral therapy in a market projected to surpass $45B in 2033. It thinks vidofludimus calcium’s opportunity in relapse-remitting MS along can support Immunic’s share outperformance.